MiniMed completes split from Medtronic

MiniMed (MMED) completed its spinoff from Medtronic, with Medtronic exchanging over 252.8 million shares. MiniMed raised $309 million in its March IPO and has a $3.1 billion product portfolio. Medtronic first announced the spinout in May 2025.

Original reporting
Published Oct 15, 2026, 3:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 4:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
MiniMed completes split from Medtronic — source image
Decision brief

The 30-second read

$MMEDNeutralMed
01

Why it matters

The completion marks the first day of independent trading, likely prompting valuation re‑rating and liquidity considerations.

02

Market read

The spinoff adds a new listed medtech stock, affecting sector dynamics and offering a focused investment thesis.

03

What to watch

Medtronic retains a large product portfolio that could limit MiniMed's growth if cross‑selling opportunities are not realized.

Relevance 7/10Novelty 7/10Timing: today

Background

MiniMed (Nasdaq: MMED) was spun out of Medtronic after an exchange offer that divested Medtronic's remaining stake.

Company-level read

Ticker impact

$MMEDNeutralHigh confidence
Context

MiniMed completed its spinoff from Medtronic, becoming an independent publicly traded company.

Expected impact

potential upside as the market prices in independence, but volatility may arise from integration risk.

Evidence & confidence

First‑report of the completion; investors will reassess valuation separate from Medtronic.

Market effects

Creates a pure-play diabetes‑tech stock, potentially sharpening peer comparisons in the medtech sector.

Limited to US markets; no broader regional effect.

Minor global relevance, mainly affecting investors focused on medtech and healthcare.

Counterpoint

The spinoff could face execution challenges and may trade below expectations if integration costs rise.

Key entities

  • MiniMed

    Independent diabetes technology company after spinoff.

  • Medtronic

    Parent company that completed the exchange offer.

Related articles

$MMEDHigh

Mizuho reiterates Outperform on MiniMed stock, cites product momentum

Mizuho reiterated an Outperform rating and $28.00 price target for MiniMed Group (MMED), citing strong product launches and regulatory approvals. The stock has gained nearly 40% over six months despite a recent 9.6% decline. MiniMed secured FDA clearance for its MiniMed Fit patch pump ahead of schedule and plans a U.S. launch in Spring 2027. Analysts predict profitability this year after a prior loss of $1.19 per share.

$MDTMed

What Piper Sandler Sees Ahead for Medtronic (MDT)

Piper Sandler upgraded Medtronic (MDT) to Overweight, raising its price target to $120 from $85. The analyst expects revenue growth driven by cardiac ablation and other products. Medtronic's Q1 2027 sales showed strong growth, and it announced acquisitions and FDA clearances. The Fed is expected to raise rates in December, impacting Treasury yields and mortgage rates.

$MDTMedAI 8/10

Radiofrequency renal denervation safe, effective in largest US trial

Medtronic's Symplicity Spyral device showed significant blood pressure reductions in the SPIRAL AFFIRM study, meeting its 6-month primary endpoint. The study, involving 594 patients, reported an 18.2 mm Hg reduction in office systolic BP, exceeding the 6 mm Hg performance goal. The results were consistent across various subgroups and showed minimal adverse events, according to data presented at TCT 2026.